Drug Approval | December 04, 2024
Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005%
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
The product will be marketed by Dr. Reddy's
Granules now has a total of 67 ANDA approvals from the USFDA
The product is expected to be launched in Q3FY25
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
